Interferons in the management of multiple myeloma.
Cooper
M R
MR
Bowman-Gray School of Medicine, Department of Hematology/Oncology, Winston-Salem, NC 27103.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004351:Drug Resistance; D006402:Hematologic Diseases / Q000209:etiology; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy / Q000628:therapy*; D011994:Recombinant Proteins; D012008:Recurrence; D014410:Tumor Stem Cell Assay
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins